Gallacher Capital Management LLC Acquires New Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Gallacher Capital Management LLC bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 4th quarter, Holdings Channel reports. The institutional investor bought 5,750 shares of the company’s stock, valued at approximately $356,000.

A number of other institutional investors have also recently modified their holdings of AMPH. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $28,000. China Universal Asset Management Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after buying an additional 628 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Amphastar Pharmaceuticals by 859.0% during the 3rd quarter. Covestor Ltd now owns 1,966 shares of the company’s stock valued at $90,000 after acquiring an additional 1,761 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Amphastar Pharmaceuticals by 115.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Annex Advisory Services LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at about $204,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 14,000 shares of company stock worth $655,145 in the last 90 days. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.22 during trading hours on Monday, hitting $42.68. The company’s stock had a trading volume of 203,974 shares, compared to its average volume of 441,774. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.06 and a 12-month high of $67.66. The business has a 50 day moving average price of $43.48 and a two-hundred day moving average price of $50.78. The company has a market cap of $2.05 billion, a PE ratio of 16.46, a PEG ratio of 1.02 and a beta of 0.85.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $66.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.